Currently, the combination of atezolizumab and bevacizumab (an anti-VEGF antibody) has become the standard of care as first-line therapy for advanced HCC, except for patients with contraindications to vascular endothelial growth factor (VEGF) inhibitors and immunotherapy [4,5]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.